Logo
  • Main site
  • ALL
  • Extension: jpeg
    Caption: Diabetes R&D, a high-accuracy digital micrometer for making oral tablets, at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Growth disorders R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Growth disorders R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Haemophilia R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Haemophilia R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Obesity R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: R&D at Novo Nordisk Oxford Research Centre, University of Oxford
    Extension: jpeg
    Caption: Obesity R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Long-term ambition is to provide access to affordable care to vulnerable patients in every country and accelerate prevention to halt the rise of diabetes.
    Extension: jpeg
    Caption: Oral semaglutide in a tablet
    Extension: jpeg
    Caption: Diabetes R&D at Novo Nordisk A/S, Denmark, 2016
    Extension: jpeg
    Caption: Diabetes R&D at Novo Nordisk A/S, Måløv, Denmark
    Extension: jpeg
    Extension: jpeg
    Caption: Novo Nordisk Research Center, Seattle, US
    Extension: jpeg
    Caption: Haemophilia R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Growth disorders R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg